Third quarter 2020 results


Sanofi Q3 2020 business EPS growth of 8.8% at CER

Third quarter 2020 results were reviewed by management during a conference call with the financial community.

(14:30 CET)

We achieved strong growth in our treatment for type 2 inflammation disorders and vaccines during Q3. We helped transform the lives of thousands of patients and reduced the spread of vaccine-preventable diseases, even as we continue to fight COVID-19.

Paul Hudson

Chief Executive Officer



Press release

Q3 2020 income statements

Q3 2020 net sales by GBU, franchise, geographic region and product

R&D appendices

Clinical trials appendices

Download infographic

Q3 2020 Memorandum for modelling purposes